Literature DB >> 8450038

Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa.

G B Pier1, S Takeda, M Grout, R B Markham.   

Abstract

We examined the basis for the absence in cystic fibrosis (CF) patients of opsonic antibodies to the mucoid exopolysaccharide (MEP) antigen surrounding Pseudomonas aeruginosa that infect these patients. Opsonic antibodies to MEP are found in sera of the minority of CF patients that remain noncolonized into the second to fourth decades of life and protect rodents from chronic P. aeruginosa endobronchial infections. High titers of nonopsonic antibodies to MEP are found in P. aeruginosa-infected CF patients. Immunization of mice with doses of MEP that provoke only nonopsonic antibodies elicited CD3+, CD8+, T cell receptor alpha beta receptor+, major histocompatibility complex-unrestricted cytotoxic lymphocytes specific for hybridoma cells producing opsonic but not nonopsonic antibodies. Cytotoxicity was dependent on immune complexes on the surface of the T cells. Normal murine T cells could be activated by concanavalin A and sensitized with immune complexes for cytotoxic killing of hybridoma targets. CF patients infected with P. aeruginosa had serum immune complexes that sensitized concanavalin A-activated human T cells to kill murine hybridoma cells producing opsonic but not nonopsonic antibody. These results could explain the absence in infected CF patients of MEP-specific opsonins, an occurrence that accompanies the persistence of this infectious state.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450038      PMCID: PMC288062          DOI: 10.1172/JCI116265

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

Review 1.  Antigen presentation by B cells and its significance in T-B interactions.

Authors:  R W Chesnut; H M Grey
Journal:  Adv Immunol       Date:  1986       Impact factor: 3.543

Review 2.  Occurrence and potential significance of increased numbers of T cells with Fc receptors in myeloma.

Authors:  R G Hoover; H M Gebel; B K Dieckgraefe; S Hickman; N F Rebbe; N Hirayama; Z Ovary; R G Lynch
Journal:  Immunol Rev       Date:  1981       Impact factor: 12.988

3.  Alginate production by clinical nonmucoid Pseudomonas aeruginosa strains.

Authors:  E D Anastassiou; A C Mintzas; C Kounavis; G Dimitracopoulos
Journal:  J Clin Microbiol       Date:  1987-04       Impact factor: 5.948

4.  Detection of antibodies to Pseudomonas aeruginosa alginate extracellular polysaccharide in animals and cystic fibrosis patients by enzyme-linked immunosorbent assay.

Authors:  L E Bryan; A Kureishi; H R Rabin
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

5.  Antibody to Pseudomonas aeruginosa mucoid exopolysaccharide and to sodium alginate in cystic fibrosis serum.

Authors:  D P Speert; D Lawton; L M Mutharia
Journal:  Pediatr Res       Date:  1984-05       Impact factor: 3.756

6.  Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide.

Authors:  P Ames; D DesJardins; G B Pier
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

7.  Immunoregulation by antigen/antibody complexes. I. Specific immunosuppression induced in vivo with immune complexes formed in antibody excess.

Authors:  M J Caulfield; D Shaffer
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

8.  Lymphocyte subpopulations and function in cystic fibrosis.

Authors:  M J Smith; L Morris; R J Stead; M E Hodson; J C Batten
Journal:  Eur J Respir Dis       Date:  1987-05

9.  Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins.

Authors:  G B Pier; M Grout; D Desjardins
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

10.  Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients.

Authors:  G B Pier; D Desjardins; T Aguilar; M Barnard; D P Speert
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

View more
  8 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection.

Authors:  David Skurnik; Michael R Davis; Dennis Benedetti; Katie L Moravec; Colette Cywes-Bentley; Damien Roux; David C Traficante; Rebecca L Walsh; Tomas Maira-Litràn; Sara K Cassidy; Christina R Hermos; Thomas R Martin; Erin L Thakkallapalli; Sara O Vargas; Alexander J McAdam; Tami D Lieberman; Roy Kishony; John J Lipuma; Gerald B Pier; Joanna B Goldberg; Gregory P Priebe
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

Review 3.  Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa.

Authors:  Rustin R Lovewell; Yash R Patankar; Brent Berwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-01-24       Impact factor: 5.464

Review 4.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

Review 5.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

6.  Pseudomonas aeruginosa exoenzyme S induces proliferation of human T lymphocytes.

Authors:  C H Mody; D E Buser; R M Syme; D E Woods
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

7.  Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.

Authors:  G B Pier; D DesJardin; M Grout; C Garner; S E Bennett; G Pekoe; S A Fuller; M O Thornton; W S Harkonen; H C Miller
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

Review 8.  State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?

Authors:  James F Chmiel; Pamela B Davis
Journal:  Respir Res       Date:  2003-08-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.